Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(83.3%)

Phase 1

1(16.7%)

6Total

Phase 2(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01943630Phase 2Unknown

Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts

Role: lead

NCT00788424Phase 2Withdrawn

Topical Application of AS101 for the Treatment of Psoriasis

Role: lead

NCT01010373Phase 2Suspended

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Role: lead

NCT00927212Phase 2Terminated

Topical Application of AS101 for the Treatment of Atopic Dermatitis

Role: lead

NCT01555112Phase 1Completed

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

Role: lead

NCT00926354Phase 2Terminated

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Role: lead

All 6 trials loaded